A Phase 3 interventional study of GFF MDI (PT003) and FF MDI (PT005) in Chronic Obstructive Pulmonary Disease, sponsored by Pearl Therapeutics, Inc.. Completed at 167 sites in 11 countries. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2019-02-20.
Sponsored by Pearl Therapeutics, Inc. (part of AstraZeneca) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive — 2 open to participants now, 2 under way, 1 of them phase 3. Glycopyrrolate · Pulmonary Disease, Chronic Obstructive.
Among the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive, this one is the 6th largest by enrollment, is one of 8 that started in 2015, is one of 33 in phase 3, and was the 44th registered.
5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →2 of the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in Germany, United Kingdom
Ages 40–80
AstraZeneca · Sites in United States, Argentina, Australia and 34 more countries
Ages 40–80
By country, each count listing its studies:
Glycopyrrolate: first FDA approval 1961 (ROBINUL FORTE), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.
This study: 40 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
73 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 21 · Phase 3 33 · Phase 4 11
First in 2005; this study’s year is marked. 8 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,756 is above the median of 62 across 3,841 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 152 across the 73 interventional studies. Of the 67 that completed or were terminated, 49 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
67 of 73 have an industry lead sponsor. The 10 most frequent:
This study is registered under Pearl Therapeutics, Inc., one of the names counted as AstraZeneca. Under that name alone:
Pearl Therapeutics, Inc. is the lead sponsor of 42 studies on the registry; none are open to participants now.
Of its 16 completed or terminated interventional studies of FDA-regulated products, 15 (94%) have results posted.
284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca: 14 open now, 15 under way, 4 of them phase 3. Of 264 finished, 127 (48%) have results posted.
Among the 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca, this one is the 13th largest by enrollment of the 194 interventional ones that give a count, is one of 19 that started in 2015, is one of 76 in phase 3, and was the 162nd registered.
AstraZeneca’s Pulmonary Disease, Chronic Obstructive studies by the year they started, since 1999.
1 of the studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07073950AstraZenecaA Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and Hyperinflation | 2027-05-31 |
Add it to your calendar (.ics) → With an account.
Among the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AstraZeneca’s 284 in Pulmonary Disease, Chronic Obstructive:
This tab as a report to print or save as PDF → With an account.
A chronic dosing (24 weeks) study to assess the efficacy and safety GFF MDI; PT003), FF MDI; PT005, and GP MDI; PT001) in subjects with moderate to very severe COPD, compared with placebo.
A randomized, double-blind, chronic dosing (24 weeks), placebo-controlled, parallel group, multi-center study to assess the efficacy and safety of glycopyrronium and formoterol fumarate inhalation aerosol (GFF; PT003), formoterol fumarate inhalation aerosol (FF; PT005), and glycopyrronium inhalation aerosol (GP; PT001) in subjects with moderate to very severe COPD, compared with placebo.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI; PT003); Glycopyrronium and Formoterol Fumarate Inhalation Aerosol administered as 2 inhalations twice-daily (BID)
Drug: GFF MDI (PT003)
Formoterol Fumarate Metered Dose Inhaler (FF MDI; PT005); Formoterol Fumarate Inhalation Aerosol administered as 2 inhalations twice-daily (BID)
Drug: FF MDI (PT005)
Glycopyrronium Metered Dose Inhaler (GP MDI; PT001); Glycopyrronium Inhalation Aerosol administered as 2 inhalations twice-daily (BID)
Drug: GP MDI (PT001)
Placebo (matching) for GFF MDI, FF MDI, and GP MDI administered as 2 inhalations twice-daily (BID)
Drug: Placebo MDI
Drug pages: Glycopyrrolate · Formoterol
Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI; PT003); Glycopyrronium and Formoterol Fumarate Inhalation Aerosol administered as 2 inhalations twice-daily (BID)
Also known as: Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI; PT003); Glycopyrronium and Formoterol Fumarate Inhalation Aerosol
Formoterol Fumarate Metered Dose Inhaler (FF MDI; PT005); Formoterol Fumarate Inhalation Aerosol administered as 2 inhalations twice-daily (BID)
Also known as: Formoterol Fumarate Metered Dose Inhaler (FF MDI; PT005); Formoterol Fumarate Inhalation Aerosol
Glycopyrronium Metered Dose Inhaler (GP MDI; PT001); Glycopyrronium Inhalation Aerosol administered as 2 inhalations twice-daily (BID)
Also known as: Glycopyrronium Metered Dose Inhaler (GP MDI; PT001); Glycopyrronium Inhalation Aerosol
Placebo (matching) for GFF MDI, FF MDI, and GP MDI administered as 2 inhalations twice-daily (BID)
Also known as: Placebo (matching) for GFF MDI, FF MDI, and GP MDI
Change From Baseline in Morning Pre-dose Trough FEV1 at Week 24 of Treatment (US/China Approach)
For the US/China approach, the primary endpoint was the change from baseline in morning pre-dose trough FEV1 at Week 24 of treatment
Time frame: at week 24
Change From Baseline in Morning Pre-dose Trough FEV1 Over Weeks 12-24, Japan Approach
Change from baseline in morning pre-dose trough FEV1 over weeks 12-24, Japan approach
Time frame: over weeks 12-24
Change From Baseline in Morning Pre-dose Trough FEV1 Over 24 Weeks. Primary Endpoint, EU/SK/TW Approach, Secondary Endpoint US/China Approach.
Change from baseline in morning pre-dose trough FEV1 over 24 weeks. Primary endpoint, EU/SK/TW approach, Secondary endpoint US/China approach.
Time frame: over 24 weeks
TDI Focal Score Over 24 Weeks, US/China and EU/SK/TW Approach
TDI focal score over 24 Weeks as a Model-Based Average (ITT Population) The TDI is an instrument which measures the changes in the participant's dyspnea from Baseline. The scores in the TDI evaluate ratings for 3 different categories (functional impairment, magnitude of task in exertional capacity, and magnitude of effort). TDI scores ranged from -3 (major deterioration) to +3 (major improvement); total score = -9 to 9
Time frame: over 24 Weeks
TDI Focal Score Over Weeks 12-24 Japan Approach
TDI focal score over 12-24 Weeks as a Model-Based Average (ITT Population) The TDI is an instrument which measures the changes in the participant's dyspnea from Baseline. The scores in the TDI evaluate ratings for 3 different categories (functional impairment, magnitude of task in exertional capacity, and magnitude of effort). TDI scores ranged from -3 (major deterioration) to +3 (major improvement); total score = -9 to 9
Time frame: over Weeks 12-24
TDI Focal Score Over 24 Weeks - US/China and EU/SK/TW Approaches -Symptomatic Population
TDI focal score over 24 Weeks as a Model-Based Average (ITT Population) The TDI is an instrument which measures the changes in the participant's dyspnea from Baseline. The scores in the TDI evaluate ratings for 3 different categories (functional impairment, magnitude of task in exertional capacity, and magnitude of effort). TDI scores ranged from -3 (major deterioration) to +3 (major improvement); total score = -9 to 9
Time frame: over 24 Weeks
TDI Focal Score Over Weeks 12-24 - Japan Approach - Symptomatic Population
TDI focal score over 12-24 Weeks as a Model-Based Average (ITT Population) The TDI is an instrument which measures the changes in the participant's dyspnea from Baseline. The scores in the TDI evaluate ratings for 3 different categories (functional impairment, magnitude of task in exertional capacity, and magnitude of effort). TDI scores ranged from -3 (major deterioration) to +3 (major improvement); total score = -9 to 9
Time frame: over weeks 12-24
Peak Change From Baseline in FEV1 Within 2 Hours Post-dosing at Week 24 US/China Approach
Peak change from baseline in FEV1 within 2 hours post-dosing at Week 24 US/China approach
Time frame: at week 24
Peak Change From Baseline in FEV1 Within 2 Hours Post-dosing Over Weeks 12-24 Japan Approach
Peak change from baseline in FEV1 within 2 hours post-dosing over weeks 12-24 Japan approach
Time frame: over weeks 12-24
Peak Change From Baseline in FEV1 Within 2 Hours Post-dosing Over 24 Weeks EU/SK/TW Approach
Peak change from baseline in FEV1 within 2 hours post-dosing over 24 weeks EU/SK/TW approach
Time frame: over 24 weeks
Change From Baseline in SGRQ Total Score at Week 24, US/China Approach
Change from baseline in the SGRQ total score. The SGRQ is a disease-specific questionnaire, self-completed by participants, used to evaluate the effect of GFF MDI, FF MDI and GP MDI on health-related quality of life as compared to placebo in subjects with COPD. The scores range from 0 (minimum, best possible health status) to 100 (maximum, worst possible health status). The SGRQ contains 76 items grouped into three domains (symptoms, activity and impacts). Change from Baseline at a particular visit was calculated as the SGRQ total score at that visit minus Baseline. Change from Baseline in total score of -4 units or lower is considered as clinically meaningful improvement in quality of life
Time frame: at week 24
Change From Baseline in SGRQ Total Score Over Weeks 12-24 , Japan & EU/SK/TW Approach
Change from baseline in the SGRQ total score. The SGRQ is a disease-specific questionnaire, self-completed by participants, used to evaluate the effect of GFF MDI, FF MDI and GP MDI on health-related quality of life as compared to placebo in subjects with COPD. The scores range from 0 (minimum, best possible health status) to 100 (maximum, worst possible health status). The SGRQ contains 76 items grouped into three domains (symptoms, activity and impacts). Change from Baseline at a particular visit was calculated as the SGRQ total score at that visit minus Baseline. Change from Baseline in total score of -4 units or lower is considered as clinically meaningful improvement in quality of life
Time frame: over weeks 12-24
Change From Baseline in SGRQ Total Score at Week 24 in Symptomatic Population, US/China Approach
Change from baseline in the SGRQ total score. The SGRQ is a disease-specific questionnaire, self-completed by participants, used to evaluate the effect of GFF MDI, FF MDI and GP MDI on health-related quality of life as compared to placebo in subjects with COPD. The scores range from 0 (minimum, best possible health status) to 100 (maximum, worst possible health status). The SGRQ contains 76 items grouped into three domains (symptoms, activity and impacts). Change from Baseline at a particular visit was calculated as the SGRQ total score at that visit minus Baseline. Change from Baseline in total score of -4 units or lower is considered as clinically meaningful improvement in quality of life
Time frame: at week 24
Change From Baseline in SGRQ Total Score Over Weeks 12-24, in Symptomatic Population, Japan & EU/SK/TW Approach
Change from baseline in the SGRQ total score. The SGRQ is a disease-specific questionnaire, self-completed by participants, used to evaluate the effect of GFF MDI, FF MDI and GP MDI on health-related quality of life as compared to placebo in subjects with COPD. The scores range from 0 (minimum, best possible health status) to 100 (maximum, worst possible health status). The SGRQ contains 76 items grouped into three domains (symptoms, activity and impacts). Change from Baseline at a particular visit was calculated as the SGRQ total score at that visit minus Baseline. Change from Baseline in total score of -4 units or lower is considered as clinically meaningful improvement in quality of life
Time frame: over weeks 12-24
Change From Baseline in Average Daily Rescue Ventolin Use Over 24 Weeks in RVU Population, All Approaches
Change from baseline in average daily rescue Ventolin use over 24 weeks in RVU population, all approaches
Time frame: over 24 weeks
FEV1 Measured at 5 Minutes Post-dose on Day 1
Onset of Action as Assessed by FEV1 Day 1 at 5 Minutes Post-Dose. Reported is the FEV1 measured at 5 minutes post-dose on Day 1 as the first time point when the difference from Placebo was statistically significant
Time frame: Assessed at 5-minutes post dose on Day 1
FEV1 Measured at 15 Minutes Post-dose on Day 1
Onset of Action as Assessed by FEV1 Day 1 at 15 Minutes Post-Dose. Reported is the FEV1 measured at 15 minutes post-dose on Day 1 as the first time point when the difference from Placebo was statistically significant
Time frame: Assessed at 15-minute post dose on Day 1
The study was conducted at 175 sites in the United States, United Kingdom, Taiwan (TW),South Korea (SK), Russia, Poland, Hungary, Germany, Czech Republic, China, and Japan from April 2015 to August 2017. The entire study period was scheduled to take approximately 30 weeks for each individual subject from the time of screening.
| Milestone | GFF MDI 14.4/9.6 ug | FF MDI 9.6 ug | GP MDI 14.4 ug | Placebo MDI |
|---|---|---|---|---|
| Started | 555 | 483 | 480 | 238 |
| Completed | 494 | 417 | 417 | 200 |
| Not completed | 61 | 66 | 63 | 38 |
| Withdrew: Adverse event | 15 | 14 | 15 | 3 |
| Withdrew: Lack of efficacy | 3 | 8 | 4 | 8 |
| Withdrew: Withdrawal by subject | 18 | 17 | 23 | 14 |
| Withdrew: Physician decision | 1 | 4 | 2 | 2 |
| Withdrew: Lost to follow-up | 5 | 5 | 3 | 1 |
| Withdrew: Protocol violation | 2 | 5 | 2 | 2 |
| Withdrew: Protocol specified criteria | 17 | 13 | 14 | 8 |
For the US/China approach, the primary endpoint was the change from baseline in morning pre-dose trough FEV1 at Week 24 of treatment
| mL | GFF MDI 14.4/9.6 ug | FF MDI 9.6 ug | GP MDI 14.4 ug | Placebo MDI |
|---|---|---|---|---|
| Change From Baseline in Morning Pre-dose Trough FEV1 at Week 24 of Treatment (US/China Approach) | 120 (102 to 138) | 47 (28 to 67) | 60 (41 to 80) | -45 (-73 to -17) |
Change from baseline in morning pre-dose trough FEV1 over weeks 12-24, Japan approach
| mL | GFF MDI 14.4/9.6 ug | FF MDI 9.6 ug | GP MDI 14.4 ug | Placebo MDI |
|---|---|---|---|---|
| Change From Baseline in Morning Pre-dose Trough FEV1 Over Weeks 12-24, Japan Approach | 128 (113 to 143) | 54 (38 to 71) | 74 (58 to 91) | -25 (-49 to -1) |
Change from baseline in morning pre-dose trough FEV1 over 24 weeks. Primary endpoint, EU/SK/TW approach, Secondary endpoint US/China approach.
| mL | GFF MDI 14.4/9.6 ug | FF MDI 9.6 ug | GP MDI 14.4 ug | Placebo MDI |
|---|---|---|---|---|
| Change From Baseline in Morning Pre-dose Trough FEV1 Over 24 Weeks. Primary Endpoint, EU/SK/TW Approach, Secondary Endpoint US/China Approach. | 135 (121 to 149) | 63 (48 to 78) | 80 (65 to 94) | -20 (-41 to 2) |
TDI focal score over 24 Weeks as a Model-Based Average (ITT Population) The TDI is an instrument which measures the changes in the participant's dyspnea from Baseline. The scores in the TDI evaluate ratings for 3 different categories (functional impairment, magnitude of task in exertional capacity, and magnitude of effort). TDI scores ranged from -3 (major deterioration) to +3 (major improvement); total score = -9 to 9
| Scores on a scale | GFF MDI 14.4/9.6 ug | FF MDI 9.6 ug | GP MDI 14.4 ug | Placebo MDI |
|---|---|---|---|---|
| TDI Focal Score Over 24 Weeks, US/China and EU/SK/TW Approach | 1.6 (1.4 to 1.8) | 1.5 (1.3 to 1.7) | 1.3 (1.1 to 1.5) | 0.8 (0.5 to 1.1) |
TDI focal score over 12-24 Weeks as a Model-Based Average (ITT Population) The TDI is an instrument which measures the changes in the participant's dyspnea from Baseline. The scores in the TDI evaluate ratings for 3 different categories (functional impairment, magnitude of task in exertional capacity, and magnitude of effort). TDI scores ranged from -3 (major deterioration) to +3 (major improvement); total score = -9 to 9
| Scores on a scale | GFF MDI 14.4/9.6 ug | FF MDI 9.6 ug | GP MDI 14.4 ug | Placebo MDI |
|---|---|---|---|---|
| TDI Focal Score Over Weeks 12-24 Japan Approach | 1.7 (1.5 to 1.9) | 1.5 (1.3 to 1.7) | 1.4 (1.2 to 1.6) | 0.8 (0.5 to 1.1) |
TDI focal score over 24 Weeks as a Model-Based Average (ITT Population) The TDI is an instrument which measures the changes in the participant's dyspnea from Baseline. The scores in the TDI evaluate ratings for 3 different categories (functional impairment, magnitude of task in exertional capacity, and magnitude of effort). TDI scores ranged from -3 (major deterioration) to +3 (major improvement); total score = -9 to 9
| Scores on a scale | GFF MDI 14.4/9.6 ug | FF MDI 9.6 ug | GP MDI 14.4 ug | Placebo MDI |
|---|---|---|---|---|
| TDI Focal Score Over 24 Weeks - US/China and EU/SK/TW Approaches -Symptomatic Population | 1.5 (1.2 to 1.7) | 1.3 (1.0 to 1.6) | 1.1 (0.8 to 1.3) | 0.7 (0.3 to 1.2) |
TDI focal score over 12-24 Weeks as a Model-Based Average (ITT Population) The TDI is an instrument which measures the changes in the participant's dyspnea from Baseline. The scores in the TDI evaluate ratings for 3 different categories (functional impairment, magnitude of task in exertional capacity, and magnitude of effort). TDI scores ranged from -3 (major deterioration) to +3 (major improvement); total score = -9 to 9
| Scores on a scale | GFF MDI 14.4/9.6 ug | FF MDI 9.6 ug | GP MDI 14.4 ug | Placebo MDI |
|---|---|---|---|---|
| TDI Focal Score Over Weeks 12-24 - Japan Approach - Symptomatic Population | 1.5 (1.2 to 1.8) | 1.4 (1.0 to 1.7) | 1.1 (0.8 to 1.4) | 0.7 (0.2 to 1.2) |
Peak change from baseline in FEV1 within 2 hours post-dosing at Week 24 US/China approach
| mL | GFF MDI 14.4/9.6 ug | FF MDI 9.6 ug | GP MDI 14.4 ug | Placebo MDI |
|---|---|---|---|---|
| Peak Change From Baseline in FEV1 Within 2 Hours Post-dosing at Week 24 US/China Approach | 358 (338 to 378) | 247 (226 to 269) | 214 (192 to 235) | 55 (24 to 87) |
Peak change from baseline in FEV1 within 2 hours post-dosing over weeks 12-24 Japan approach
| mL | GFF MDI 14.4/9.6 ug | FF MDI 9.6 ug | GP MDI 14.4 ug | Placebo MDI |
|---|---|---|---|---|
| Peak Change From Baseline in FEV1 Within 2 Hours Post-dosing Over Weeks 12-24 Japan Approach | 368 (350 to 386) | 255 (236 to 274) | 228 (209 to 248) | 70 (42 to 98) |
Peak change from baseline in FEV1 within 2 hours post-dosing over 24 weeks EU/SK/TW approach
| mL | GFF MDI 14.4/9.6 ug | FF MDI 9.6 ug | GP MDI 14.4 ug | Placebo MDI |
|---|---|---|---|---|
| Peak Change From Baseline in FEV1 Within 2 Hours Post-dosing Over 24 Weeks EU/SK/TW Approach | 375 (360 to 389) | 277 (261 to 293) | 234 (218 to 250) | 82 (58 to 105) |
Change from baseline in the SGRQ total score. The SGRQ is a disease-specific questionnaire, self-completed by participants, used to evaluate the effect of GFF MDI, FF MDI and GP MDI on health-related quality of life as compared to placebo in subjects with COPD. The scores range from 0 (minimum, best possible health status) to 100 (maximum, worst possible health status). The SGRQ contains 76 items grouped into three domains (symptoms, activity and impacts). Change from Baseline at a particular visit was calculated as the SGRQ total score at that visit minus Baseline. Change from Baseline in total score of -4 units or lower is considered as clinically meaningful improvement in quality of life
| Scores on a scale | GFF MDI 14.4/9.6 ug | FF MDI 9.6 ug | GP MDI 14.4 ug | Placebo MDI |
|---|---|---|---|---|
| Change From Baseline in SGRQ Total Score at Week 24, US/China Approach | -5.3 (-6.4 to -4.2) | -5.6 (-6.8 to -4.4) | -3.7 (-4.8 to -2.5) | -0.9 (-2.6 to 0.8) |
Change from baseline in the SGRQ total score. The SGRQ is a disease-specific questionnaire, self-completed by participants, used to evaluate the effect of GFF MDI, FF MDI and GP MDI on health-related quality of life as compared to placebo in subjects with COPD. The scores range from 0 (minimum, best possible health status) to 100 (maximum, worst possible health status). The SGRQ contains 76 items grouped into three domains (symptoms, activity and impacts). Change from Baseline at a particular visit was calculated as the SGRQ total score at that visit minus Baseline. Change from Baseline in total score of -4 units or lower is considered as clinically meaningful improvement in quality of life
| Scores on a scale | GFF MDI 14.4/9.6 ug | FF MDI 9.6 ug | GP MDI 14.4 ug | Placebo MDI |
|---|---|---|---|---|
| Change From Baseline in SGRQ Total Score Over Weeks 12-24 , Japan & EU/SK/TW Approach | -5.2 (-6.1 to -4.3) | -5.0 (-5.9 to -4.0) | -3.6 (-4.6 to -2.6) | -1.7 (-3.1 to -0.3) |
Change from baseline in the SGRQ total score. The SGRQ is a disease-specific questionnaire, self-completed by participants, used to evaluate the effect of GFF MDI, FF MDI and GP MDI on health-related quality of life as compared to placebo in subjects with COPD. The scores range from 0 (minimum, best possible health status) to 100 (maximum, worst possible health status). The SGRQ contains 76 items grouped into three domains (symptoms, activity and impacts). Change from Baseline at a particular visit was calculated as the SGRQ total score at that visit minus Baseline. Change from Baseline in total score of -4 units or lower is considered as clinically meaningful improvement in quality of life
| Scores on a scale | GFF MDI 14.4/9.6 ug | FF MDI 9.6 ug | GP MDI 14.4 ug | Placebo MDI |
|---|---|---|---|---|
| Change From Baseline in SGRQ Total Score at Week 24 in Symptomatic Population, US/China Approach | -6.9 (-8.6 to -5.2) | -7.8 (-9.7 to -5.9) | -3.8 (-5.6 to -2.0) | -1.6 (-4.3 to 1.1) |
Change from baseline in the SGRQ total score. The SGRQ is a disease-specific questionnaire, self-completed by participants, used to evaluate the effect of GFF MDI, FF MDI and GP MDI on health-related quality of life as compared to placebo in subjects with COPD. The scores range from 0 (minimum, best possible health status) to 100 (maximum, worst possible health status). The SGRQ contains 76 items grouped into three domains (symptoms, activity and impacts). Change from Baseline at a particular visit was calculated as the SGRQ total score at that visit minus Baseline. Change from Baseline in total score of -4 units or lower is considered as clinically meaningful improvement in quality of life
| Scores on a scale | GFF MDI 14.4/9.6 ug | FF MDI 9.6 ug | GP MDI 14.4 ug | Placebo MDI |
|---|---|---|---|---|
| Change From Baseline in SGRQ Total Score Over Weeks 12-24, in Symptomatic Population, Japan & EU/SK/TW Approach | -6.9 (-8.4 to -5.4) | -7.3 (-8.9 to -5.6) | -3.9 (-5.5 to -2.4) | -3.1 (-5.4 to -0.8) |
Change from baseline in average daily rescue Ventolin use over 24 weeks in RVU population, all approaches
| Puffs/day | GFF MDI 14.4/9.6 ug | FF MDI 9.6 ug | GP MDI 14.4 ug | Placebo MDI |
|---|---|---|---|---|
| Change From Baseline in Average Daily Rescue Ventolin Use Over 24 Weeks in RVU Population, All Approaches | -1.4 (-1.7 to -1.1) | -1.0 (-1.3 to -0.7) | -0.6 (-0.9 to -0.3) | -0.4 (-0.8 to -0.0) |
Onset of Action as Assessed by FEV1 Day 1 at 5 Minutes Post-Dose. Reported is the FEV1 measured at 5 minutes post-dose on Day 1 as the first time point when the difference from Placebo was statistically significant
| Liters | GFF MDI 14.4/9.6 ug | FF MDI 9.6 ug | GP MDI 14.4 ug | Placebo MDI |
|---|---|---|---|---|
| FEV1 Measured at 5 Minutes Post-dose on Day 1 | 0.202 (0.191 to 0.212) | 0.186 (0.175 to 0.197) | 0.059 (0.048 to 0.070) | 0.022 (0.006 to 0.038) |
Onset of Action as Assessed by FEV1 Day 1 at 15 Minutes Post-Dose. Reported is the FEV1 measured at 15 minutes post-dose on Day 1 as the first time point when the difference from Placebo was statistically significant
| Liters | GFF MDI 14.4/9.6 ug | FF MDI 9.6 ug | GP MDI 14.4 ug | Placebo MDI |
|---|---|---|---|---|
| FEV1 Measured at 15 Minutes Post-dose on Day 1 | 0.241 (0.230 to 0.252) | 0.220 (0.208 to 0.231) | 0.105 (0.093 to 0.117) | 0.033 (0.016 to 0.050) |
Collected over Adverse events were collected from the time the subject signed consent throughout the four treatment periods of 24 weeks and up to 10 days following the last dose of study drug.. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| GFF MDI 14.4/9.6 ug | 1/551 (0.2%) | 53/551 (9.6%) | 166/551 (30.1%) |
| FF MDI 9.6 ug | 1/480 (0.2%) | 40/480 (8.3%) | 123/480 (25.6%) |
| GP MDI 14.4 ug | 1/474 (0.2%) | 34/474 (7.2%) | 128/474 (27%) |
| Placebo MDI | 1/235 (0.4%) | 19/235 (8.1%) | 61/235 (26%) |
| Event | GFF MDI 14.4/9.6 ug | FF MDI 9.6 ug | GP MDI 14.4 ug | Placebo MDI |
|---|---|---|---|---|
| Chronic Obstructive Pulmonary DiseaseRespiratory, thoracic and mediastinal disorders | 16/551 | 13/480 | 12/474 | 7/235 |
| PneumoniaInfections and infestations | 7/551 | 2/480 | 3/474 | 3/235 |
| CellulitisInfections and infestations | 3/551 | 0/480 | 0/474 | 0/235 |
| PneumothoraxRespiratory, thoracic and mediastinal disorders | 0/551 | 0/480 | 1/474 | 1/235 |
| Gastrointestinal InfectionInfections and infestations | 0/551 | 0/480 | 0/474 | 1/235 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 1/551 | 0/480 | 0/474 | 1/235 |
| Lung cancer metastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/551 | 0/480 | 0/474 | 1/235 |
| Cardiac myxomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/551 | 0/480 | 0/474 | 1/235 |
| Papillary thyroid cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/551 | 0/480 | 0/474 | 1/235 |
| Rib fractureInjury, poisoning and procedural complications | 1/551 | 0/480 | 0/474 | 1/235 |
| Event | GFF MDI 14.4/9.6 ug | FF MDI 9.6 ug | GP MDI 14.4 ug | Placebo MDI |
|---|---|---|---|---|
| Viral upper respiratory tract infectionInfections and infestations | 50/551 | 46/480 | 44/474 | 16/235 |
| Upper respiratory tract infectionInfections and infestations | 37/551 | 29/480 | 33/474 | 20/235 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 16/551 | 13/480 | 12/474 | 7/235 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 11/551 | 7/480 | 6/474 | 7/235 |
| Back PainMusculoskeletal and connective tissue disorders | 15/551 | 5/480 | 7/474 | 1/235 |
| PneumoniaInfections and infestations | 9/551 | 5/480 | 5/474 | 6/235 |
| CoughRespiratory, thoracic and mediastinal disorders | 13/551 | 8/480 | 10/474 | 2/235 |
| BronchitisInfections and infestations | 4/551 | 6/480 | 8/474 | 5/235 |
| PharyngitisInfections and infestations | 11/551 | 4/480 | 3/474 | 0/235 |
The data reported from one site was not included in the final analysis.
| Age, Continuous(Years) | GFF MDI 14.4/9.6 ug | FF MDI 9.6 ug | GP MDI 14.4 ug | Placebo MDI | Total |
|---|---|---|---|---|---|
| Mean | 64.7 ± 7.4 | 64.1 ± 7.6 | 64.0 ± 8.1 | 63.9 ± 7.5 | 64.2 ± 7.7 |
| Sex: Female, Male(Participants) | GFF MDI 14.4/9.6 ug | FF MDI 9.6 ug | GP MDI 14.4 ug | Placebo MDI | Total |
|---|---|---|---|---|---|
| Female | 143 | 115 | 128 | 64 | 450 |
| Male | 408 | 365 | 346 | 171 | 1290 |
| Race (NIH/OMB)(Participants) | GFF MDI 14.4/9.6 ug | FF MDI 9.6 ug | GP MDI 14.4 ug | Placebo MDI | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 0 | 0 | 1 |
| Asian | 223 | 204 | 181 | 92 | 700 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 12 | 16 | 18 | 6 | 52 |
| White | 315 | 260 | 275 | 137 | 987 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
Showing the first 100 of 167 sites across 11 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — AstraZeneca's policy is to share data with researchers if the request is in scope of our policy. The policy and additional information can be found on astrazenecaclinicaltrials.com.
Ran from Mar 2015 to primary completion in Aug 2017, 29 months.
Results were first posted in Feb 2019, 1 year 5 months after primary completion.
Of 108 industry-sponsored phase 3 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 36. This study's 29 months is above that.
Counting every sponsor, half of 141 studies reached it within 23 months; a quarter within 14 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Glycopyrrolate · Formoterol
Pulmonary Disease, Chronic Obstructive →